Oncimmune discuss their highly profitable ImmunoINSIGHTS business
(ONC ) CEO, Dr Adam M Hill, discusses how the highly profitable ImmunoINSIGHTS business, the Company's autoantibody profiling service, is used by their big pharma clients and their fixed pricing model. Adam goes on to discusses the lack of competition and how they are only addressing circa 3% of a huge markets but the the hiring of key staff and increasing the business development team in the UK and the USA will allow further growth.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.